Vir Biotechnology Net Income
| VIR Stock | USD 7.51 0.23 3.16% |
As of the 10th of February, Vir Biotechnology has the Risk Adjusted Performance of 0.115, coefficient of variation of 751.0, and Semi Deviation of 3.4. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vir Biotechnology, as well as the relationship between them. Please validate Vir Biotechnology jensen alpha and semi variance to decide if Vir Biotechnology is priced more or less accurately, providing market reflects its prevalent price of 7.51 per share. Given that Vir Biotechnology has jensen alpha of 0.4307, we advise you to double-check Vir Biotechnology's current market performance to make sure the company can sustain itself at a future point.
Vir Biotechnology Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 42.2621 | Revenue | Earnings Share (3.62) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -469.8 M | -446.3 M | |
| Net Income Applicable To Common Shares | 593.2 M | 622.9 M | |
| Net Loss | -469.8 M | -446.3 M | |
| Net Loss | (3.45) | (3.28) | |
| Net Income Per E B T | 1.15 | 1.03 |
Vir | Net Income | Build AI portfolio with Vir Stock |
Evaluating Vir Biotechnology's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Vir Biotechnology's fundamental strength.
Latest Vir Biotechnology's Net Income Growth Pattern
Below is the plot of the Net Income of Vir Biotechnology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Vir Biotechnology financial statement analysis. It represents the amount of money remaining after all of Vir Biotechnology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Vir Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vir Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (521.96 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Vir Net Income Regression Statistics
| Arithmetic Mean | (126,863,988) | |
| Coefficient Of Variation | (242.53) | |
| Mean Deviation | 207,673,514 | |
| Median | (69,852,000) | |
| Standard Deviation | 307,677,171 | |
| Sample Variance | 94665.2T | |
| Range | 1.1B | |
| R-Value | (0.31) | |
| Mean Square Error | 91354T | |
| R-Squared | 0.1 | |
| Significance | 0.23 | |
| Slope | (18,808,481) | |
| Total Sum of Squares | 1514643.9T |
Vir Net Income History
Other Fundumenentals of Vir Biotechnology
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Vir Biotechnology Net Income component correlations
Vir Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vir Biotechnology is extremely important. It helps to project a fair market value of Vir Stock properly, considering its historical fundamentals such as Net Income. Since Vir Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vir Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vir Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Vir have expansion opportunities? Factors like these will boost the valuation of Vir Biotechnology. If investors know Vir will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Vir Biotechnology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth 0.585 | Earnings Share (3.62) | Revenue Per Share | Quarterly Revenue Growth (0.90) | Return On Assets |
Vir Biotechnology's market price often diverges from its book value, the accounting figure shown on Vir's balance sheet. Smart investors calculate Vir Biotechnology's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Vir Biotechnology's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Vir Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vir Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vir Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vir Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vir Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vir Biotechnology.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Vir Biotechnology on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Vir Biotechnology or generate 0.0% return on investment in Vir Biotechnology over 90 days. Vir Biotechnology is related to or competes with Maravai Lifesciences, Iovance Biotherapeutics, Replimune, Prime Medicine, Ginkgo Bioworks, Geron, and LENZ Therapeutics. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serio... More
Vir Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vir Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vir Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.83 | |||
| Information Ratio | 0.111 | |||
| Maximum Drawdown | 23.4 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 8.08 |
Vir Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vir Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vir Biotechnology's standard deviation. In reality, there are many statistical measures that can use Vir Biotechnology historical prices to predict the future Vir Biotechnology's volatility.| Risk Adjusted Performance | 0.115 | |||
| Jensen Alpha | 0.4307 | |||
| Total Risk Alpha | 0.0923 | |||
| Sortino Ratio | 0.129 | |||
| Treynor Ratio | 0.3401 |
Vir Biotechnology February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.115 | |||
| Market Risk Adjusted Performance | 0.3501 | |||
| Mean Deviation | 3.38 | |||
| Semi Deviation | 3.4 | |||
| Downside Deviation | 3.83 | |||
| Coefficient Of Variation | 751.0 | |||
| Standard Deviation | 4.44 | |||
| Variance | 19.75 | |||
| Information Ratio | 0.111 | |||
| Jensen Alpha | 0.4307 | |||
| Total Risk Alpha | 0.0923 | |||
| Sortino Ratio | 0.129 | |||
| Treynor Ratio | 0.3401 | |||
| Maximum Drawdown | 23.4 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 8.08 | |||
| Downside Variance | 14.64 | |||
| Semi Variance | 11.54 | |||
| Expected Short fall | (3.84) | |||
| Skewness | 0.6422 | |||
| Kurtosis | 1.33 |
Vir Biotechnology Backtested Returns
Vir Biotechnology appears to be slightly risky, given 3 months investment horizon. Vir Biotechnology owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.12, which indicates the firm had a 0.12 % return per unit of risk over the last 3 months. By inspecting Vir Biotechnology's technical indicators, you can evaluate if the expected return of 0.56% is justified by implied risk. Please review Vir Biotechnology's Semi Deviation of 3.4, coefficient of variation of 751.0, and Risk Adjusted Performance of 0.115 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Vir Biotechnology holds a performance score of 9. The entity has a beta of 1.71, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vir Biotechnology will likely underperform. Please check Vir Biotechnology's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Vir Biotechnology's existing price patterns will revert.
Auto-correlation | 0.67 |
Good predictability
Vir Biotechnology has good predictability. Overlapping area represents the amount of predictability between Vir Biotechnology time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vir Biotechnology price movement. The serial correlation of 0.67 indicates that around 67.0% of current Vir Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.67 | |
| Spearman Rank Test | 0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.54 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vir Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vir Biotechnology reported net income of (521.96 Million). This is 252.94% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 191.41% higher than that of the company.
Vir Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vir Biotechnology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vir Biotechnology could also be used in its relative valuation, which is a method of valuing Vir Biotechnology by comparing valuation metrics of similar companies.Vir Biotechnology is currently under evaluation in net income category among its peers.
Vir Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vir Biotechnology from analyzing Vir Biotechnology's financial statements. These drivers represent accounts that assess Vir Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vir Biotechnology's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.2B | 5.4B | 3.4B | 1.3B | 1.2B | 1.8B | |
| Enterprise Value | 2.8B | 5.2B | 2.6B | 1.2B | 1.1B | 1.6B |
Vir Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vir Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vir Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Vir Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Vir Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Vir Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vir Biotechnology's value.| Shares | Charles Schwab Investment Management Inc | 2025-06-30 | 1.3 M | Goldman Sachs Group Inc | 2025-06-30 | 1.3 M | Ikarian Capital, Llc | 2025-06-30 | 1.1 M | Renaissance Technologies Corp | 2025-06-30 | 1.1 M | Aberdeen Group Plc | 2025-06-30 | 1 M | Northern Trust Corp | 2025-06-30 | 928.2 K | Schroder Investment Management Group | 2025-06-30 | 840.4 K | Artisan Partners Limited Partnership | 2025-06-30 | 791.6 K | Voloridge Investment Management, Llc | 2025-06-30 | 789.5 K | Sb Investment Advisers (uk) Ltd | 2025-06-30 | 16.7 M | Blackrock Inc | 2025-06-30 | 16.2 M |
Vir Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (722.68) % | ||||
| Current Valuation | 593.28 M | ||||
| Shares Outstanding | 139.13 M | ||||
| Shares Owned By Insiders | 10.38 % | ||||
| Shares Owned By Institutions | 78.50 % | ||||
| Number Of Shares Shorted | 12 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 59.33 X | ||||
| Revenue | 74.2 M | ||||
| Gross Profit | (427.98 M) | ||||
| EBITDA | (508.91 M) | ||||
| Net Income | (521.96 M) | ||||
| Cash And Equivalents | 2.2 B | ||||
| Cash Per Share | 16.55 X | ||||
| Total Debt | 97.89 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.79 X | ||||
| Book Value Per Share | 5.73 X | ||||
| Cash Flow From Operations | (446.35 M) | ||||
| Short Ratio | 6.43 X | ||||
| Earnings Per Share | (3.62) X | ||||
| Price To Earnings To Growth | 1.14 X | ||||
| Target Price | 16.33 | ||||
| Number Of Employees | 408 | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 1 B | ||||
| Total Asset | 1.4 B | ||||
| Retained Earnings | (759.78 M) | ||||
| Working Capital | 922.8 M | ||||
| Net Asset | 1.4 B |
About Vir Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vir Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vir Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vir Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with Vir Stock
Moving against Vir Stock
| 0.7 | LYRA | Lyra Therapeutics | PairCorr |
| 0.68 | ABP | Abpro Holdings | PairCorr |
| 0.66 | GNLX | Genelux Common | PairCorr |
| 0.55 | KURA | Kura Oncology | PairCorr |
| 0.52 | EDIT | Editas Medicine | PairCorr |
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.